Kovaleva Olga V, Rashidova Madina A, Sinyov Vasiliy V, Malashenko Olga S, Gratchev Alexei
Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Center for Molecular and Cellular Biology, Skolkovo Institute of Science and Technology, Moscow, Russia.
Front Immunol. 2025 Jul 31;16:1638102. doi: 10.3389/fimmu.2025.1638102. eCollection 2025.
The anti-tumor role of the immune system has long been associated with interferon-γ-mediated activation of immune cells and their ability to recognize and eliminate transformed cells. Fundamental principles of tumor immunoediting describe a dynamic interplay between the immune system and neoplastic cells, wherein immune pressure can paradoxically shape tumor evolution. Within this context, macrophages, natural killer cells, and T lymphocytes are central effectors of anti-tumor immunity. Traditionally, macrophages exhibiting M1 phenotype are characterized by high cytotoxic potential and considered important contributors to tumor eradication. In contrast, M2-polarized tumor-associated macrophages are associated with immune suppression and tumor progression. However, recent evidence challenges this binary paradigm. It is increasingly evident that M1 macrophages, while initially exerting anti-tumor effects, can also promote tumor progression by applying sustained cytotoxic pressure that selects for more malignant and immune-resistant tumor clones. This phenomenon represents an unexpected and overlooked contribution of cytotoxic macrophages to tumor progression. In this review, we examine the complex, context-dependent function of M1 macrophages and reassess current strategies aimed at enhancing their cytotoxicity. While such approaches may offer short-term benefits, they risk driving clonal selection of aggressive, immune-evasive tumor cells. Therefore, we propose a paradigm shift: instead of promoting M1 polarization alone, therapeutic strategies should consider the broader consequences of macrophage-tumor interactions. A nuanced understanding of macrophage plasticity and tumor dynamics is essential for designing effective immunotherapies. Recognizing the paradoxical role of M1 macrophages is critical to avoiding unintended support of tumor evolution and improving treatment outcomes.
免疫系统的抗肿瘤作用长期以来一直与干扰素-γ介导的免疫细胞激活及其识别和消除转化细胞的能力相关。肿瘤免疫编辑的基本原理描述了免疫系统与肿瘤细胞之间的动态相互作用,其中免疫压力可能反常地塑造肿瘤的进化。在此背景下,巨噬细胞、自然杀伤细胞和T淋巴细胞是抗肿瘤免疫的核心效应器。传统上,表现出M1表型的巨噬细胞具有高细胞毒性潜力,被认为是肿瘤根除的重要贡献者。相比之下,M2极化的肿瘤相关巨噬细胞与免疫抑制和肿瘤进展相关。然而,最近的证据对这种二元范式提出了挑战。越来越明显的是,M1巨噬细胞虽然最初发挥抗肿瘤作用,但也可以通过施加持续的细胞毒性压力来促进肿瘤进展,这种压力会选择更具恶性和免疫抗性的肿瘤克隆。这种现象代表了细胞毒性巨噬细胞对肿瘤进展的意外和被忽视的贡献。在这篇综述中,我们研究了M1巨噬细胞复杂的、依赖于上下文的功能,并重新评估了旨在增强其细胞毒性的当前策略。虽然这些方法可能会带来短期益处,但它们有推动侵袭性、免疫逃逸肿瘤细胞克隆选择的风险。因此,我们提出了一种范式转变:治疗策略不应仅促进M1极化,而应考虑巨噬细胞与肿瘤相互作用的更广泛后果。对巨噬细胞可塑性和肿瘤动态的细致理解对于设计有效的免疫疗法至关重要。认识到M1巨噬细胞的矛盾作用对于避免无意中支持肿瘤进化和改善治疗结果至关重要。